Added to YB: 2025-12-04
Pitch date: 2025-12-02
VTGN [bearish]
Vistagen Therapeutics, Inc.
+82.3%
current return
Author Info
Biotenic is a freelance L/S biotech investment analyst sharing investment theses. Sign up for the newsletter.
Company Info
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders.
Market Cap
$23.8M
Pitch Price
$3.60
Price Target
1.50 (+135%)
Dividend
N/A
EV/EBITDA
0.53
P/E
-0.32
EV/Sales
-46.34
Sector
Biotechnology
Category
special_situation
VTGN Ph3 PALISADE-3 Upcoming Readout
VTGN (short): Developing fasedienol nasal spray for social anxiety. Split Ph3 results: PALISADE-1 failed (p=0.5), PALISADE-2 positive but stopped early via unplanned interim. Blames COVID for failure despite timeline inconsistencies. Weak Ph2 data, no publications, diluted 30% via ATM pre-readout. Dec data catalyst likely negative.
Read full article (9 min)